Hengrui Medicine boosts employee incentives with A-share buyback program

Jiangsu Hengrui Medicine announced significant progress in its A-share repurchase program as of September 30, 2025. The company repurchased 4,572,400 A-shares through concentrated bidding on the Shanghai Stock Exchange, representing 0.07% of its total share capital. These shares were acquired at prices ranging from RMB 67.20 to RMB 70.00, with a total expenditure of RMB 315,404,200 (excluding transaction fees). These repurchased shares will be used for the company's A-share employee stock ownership plans, including those adopted in 2022, 2023, 2024, and 2025.

The repurchases during September 2025 included multiple transactions, with shares bought at various prices across different dates. Following these transactions, the number of A-shares held in inventory increased by 4,572,400, bringing the total to 12,923,710.

The company also conducted an additional repurchase of 110,000 A-shares on October 9, 2025, at prices between RMB 69.2 and RMB 69.81, totaling RMB 7,626,700. These shares are also intended for employee stock ownership plans, further underscoring the company's commitment to aligning employee interests with shareholder value.